Cargando…

Barriers to Mesalamine Adherence in Patients with Inflammatory Bowel Disease: A Qualitative Analysis

BACKGROUND: The causes for nonadherence to mesalamine in patients with inflammatory bowel disease (IBD) have been characterized using mostly indirect methods. Patient-reported barriers are lacking in this population. OBJECTIVES: To identify patient-reported barriers to mesalamine adherence through d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Devlen, Jennifer, Beusterien, Kathleen, Yen, Linnette, Ahmed, Awais, Cheifetz, Adam S., Moss, Alan C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437525/ https://www.ncbi.nlm.nih.gov/pubmed/24564811 http://dx.doi.org/10.18553/jmcp.2014.20.3.309

Ejemplares similares

The relationship among multiple patient-reported outcomes measures for patients with ulcerative colitis receiving treatment with MMX(®) formulated delayed-release mesalamine
por: Yarlas, Aaron, et al.
Publicado: (2014)

Mesalamine - A Revered Drug for Inflammatory Bowel Disease With Detrimental Effects on the Lung and Heart
por: Chaudhry, Ahtshamullah, et al.
Publicado: (2023)

Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine
por: Nanda, Kavinderjit, et al.
Publicado: (2012)

Mesalamine-Induced Myocarditis
por: Merceron, Olivier, et al.
Publicado: (2010)

Mesalamine Associated Bradycardia
por: Krzyzak, Michael, et al.
Publicado: (2018)

Biologic Concentration Testing in Inflammatory Bowel Disease
por: Vaughn, Byron P., et al.
Publicado: (2015)

Drug Clearance in Patients with Inflammatory Bowel Disease Treated with Biologics
por: Deyhim, Tina, et al.
Publicado: (2023)

Infliximab in inflammatory bowel disease
por: Papamichael, Konstantinos, et al.
Publicado: (2019)

Clinician Adherence to Inflammatory Bowel Disease Guidelines: Results of a Qualitative Study of Barriers and Enablers
por: Kanazaki, Ria, et al.
Publicado: (2022)

Mesalamine induced eosinophilic pneumonia
por: Gupta, Ankit, et al.
Publicado: (2017)

Characterization of Human CD39(+) Th17 Cells with Suppressor Activity and Modulation in Inflammatory Bowel Disease
por: Longhi, Maria Serena, et al.
Publicado: (2014)

Combined Treatment with Hyaluronic Acid and Mesalamine Protects Rats from Inflammatory Bowel Disease Induced by Intracolonic Administration of Trinitrobenzenesulfonic Acid
por: Chiu, Chih-Tung, et al.
Publicado: (2017)

Mesalamine and azathioprine modulate junctional complexes and restore epithelial barrier function in intestinal inflammation
por: Khare, Vineeta, et al.
Publicado: (2019)

The role of mesalamine in the treatment of ulcerative colitis
por: Karagozian, Raffi, et al.
Publicado: (2007)

Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine. [Corrigendum]
por: Nanda, K, et al.
Publicado: (2013)

Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database
por: Lachaine, Jean, et al.
Publicado: (2013)

A primer on common supplements and dietary measures used by patients with inflammatory bowel disease
por: Minhas, Hadi J, et al.
Publicado: (2023)

Gastric Pharmacobezoar of Mesalamine Tablets Retrieved Endoscopically
por: Sultania, Surender, et al.
Publicado: (2017)

Mesalamine Intolerance in Three Children with Crohn's Disease
por: Tuna Kirsaclioglu, Ceyda, et al.
Publicado: (2016)

Oral 5-Aminosalicylate, Mesalamine Suppository, and Mesalamine Enema as Initial Therapy for Ulcerative Proctitis in Clinical Practice with Quality of Care Implications
por: Richter, James M., et al.
Publicado: (2016)

The culprit of mesalamine intolerance: case series and literature review
por: Xie, Cheng, et al.
Publicado: (2019)

Retrospective investigation of mesalamine intolerance in patients with ulcerative colitis
por: Minagawa, Yuki, et al.
Publicado: (2022)

Recurrent Pericarditis: A Rare Adverse Effect of Mesalamine
por: Karki, Pratul, et al.
Publicado: (2023)

Posterior reversible encephalopathy syndrome with PLEDs-plus due to mesalamine
por: Cherian, Ajith, et al.
Publicado: (2014)

Red-Brown Urine Discolouration in Two Patients Taking Mesalamine
por: Smeets, Tim, et al.
Publicado: (2016)

Mesalamine-Induced Myopericarditis: A Case Report and Literature Review
por: Taha, Mohamed E., et al.
Publicado: (2019)

Treatment of lichen planus pemphigoides with mesalamine: novel use of this drug()
por: Gandhi, Vijay, et al.
Publicado: (2022)

Effectiveness of Mesalamine in Patients With Ulcerative Colitis: A Systematic Review
por: Santos, Yurianna, et al.
Publicado: (2023)

Medication adherence in inflammatory bowel disease
por: Chan, Webber, et al.
Publicado: (2017)

The patient experience with fatigue and content validity of a measure to assess fatigue severity: qualitative research in patients with ankylosing spondylitis (AS)
por: Naegeli, April N, et al.
Publicado: (2013)

Recurrent Inflammatory Myositis as an Extra-Intestinal Manifestation of Dormant Ulcerative Colitis in a Patient on Long-Term Mesalamine
por: Naramala, Srikanth, et al.
Publicado: (2019)

Patient Preferences for Chronic Myeloid Leukemia Medication Regimen Attributes and their Potential Impact on Adherence: Results from a Multi-national Conjoint Study
por: Hirji, Ishan, et al.
Publicado: (2014)

Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis
por: Mitra, Debanjali, et al.
Publicado: (2012)

Vedolizumab Serum Trough Concentrations and Response to Dose Escalation in Inflammatory Bowel Disease
por: Vaughn, Byron P., et al.
Publicado: (2020)

Fr103 STRATIFYING THE IMPACT OF COVID-19 PANDEMIC ON THE EMOTIONAL AND PHYSICAL WELL-BEING OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE.
por: El-Dallal, Mohammed, et al.
Publicado: (2021)

Development of Antibodies to Ustekinumab Is Associated with Loss of Response in Patients with Inflammatory Bowel Disease
por: Roblin, Xavier, et al.
Publicado: (2023)

Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis
por: Kedia, Prashant, et al.
Publicado: (2007)

Development and Validation of Spectrophotometric Methods for the Estimation of Mesalamine in Tablet Dosage Forms
por: Patel, KM, et al.
Publicado: (2010)

Dissolution of Commercially Available Mesalamine Formulations at Various pH Levels
por: Tenjarla, Srini
Publicado: (2015)

Myocarditis Secondary to Mesalamine-Induced Cardiotoxicity in a Patient with Ulcerative Colitis
por: Okoro, Kelechukwu U., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_c0i6udaj2r9841acr62ghnutfh